CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Humacyte Q3 net loss narrows 11% year over year to $15.54 million

By Public Technologies
  • Humacyte’s third-quarter 2026 net loss narrowed 11% year-over-year to $15.54 million, primarily due to lower research and development expenses.
  • Total revenue climbed 37% year-over-year to $1.03 million.
  • Symvess revenue more than doubled quarter-over-quarter to $1.02 million; fourth-quarter 2026 revenue is expected to at least double sequentially.
  • A supplemental FDA application to add dialysis access as an approved ATEV indication remains planned for November 2026.
  • A first-in-human Phase 2a study of CTEV in coronary artery bypass grafting began in November 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873994) on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.